Bausch + Lomb Corporation (NYSE:BLCO – Get Free Report) has been assigned a consensus recommendation of “Hold” from the fifteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $21.08.
A number of equities research analysts have recently issued reports on BLCO shares. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research note on Tuesday, September 15th. Wells Fargo & Company increased their price objective on Bausch + Lomb from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Thursday, October 29th. Royal Bank Of Canada raised their target price on shares of Bausch + Lomb from $21.00 to $23.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. Finally, HC Wainwright downgraded shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $21.00 to $22.00 in a report on Monday, November 2nd.
Read Our Latest Report on Bausch + Lomb
Bausch + Lomb Stock Performance
Bausch + Lomb (NYSE:BLCO – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.21 by $0.13. The firm had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.37 billion. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 earnings per share. As a group, sell-side analysts expect that Bausch + Lomb will post 0.94 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $20.48, for a total value of $2,294,067.20. Following the completion of the transaction, the chief accounting officer owned 45,831 shares of the company’s stock, valued at $938,618.88. This trade represents a 70.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.45% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Bausch + Lomb
A number of institutional investors and hedge funds have recently modified their holdings of the company. Roxbury Financial LLC acquired a new stake in shares of Bausch + Lomb in the third quarter valued at approximately $33,000. Royal Bank of Canada boosted its stake in shares of Bausch + Lomb by 67.1% during the 1st quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock worth $58,000 after acquiring an additional 1,468 shares during the period. State of Wyoming boosted its stake in shares of Bausch + Lomb by 6.9% during the 3rd quarter. State of Wyoming now owns 13,772 shares of the company’s stock worth $234,000 after acquiring an additional 887 shares during the period. R Squared Ltd boosted its stake in shares of Bausch + Lomb by 46.0% during the 3rd quarter. R Squared Ltd now owns 17,452 shares of the company’s stock worth $297,000 after acquiring an additional 5,502 shares during the period. Finally, Handelsbanken Fonder AB raised its stake in Bausch + Lomb by 5.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock valued at $364,000 after acquiring an additional 1,100 shares during the period. 11.07% of the stock is owned by institutional investors.
Bausch + Lomb Company Profile
Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.
Featured Stories
- Five stocks we like better than Bausch + Lomb
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
